Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Estracyt in HR+/HER2- Metastatic Breast Cancer
NCT02853071Phase 2Withdrawn
- Sponsor
- CHU de Besançon
- Start
- Jan 2017
- Primary completion
- Jan 2020
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of estramustine in breast cancer (2 arms), sponsored by CHU de Besançon. Primary endpoint: Proportion of the alive patients without progress of the disease at 3 months. Planned start Jan 2017; status: withdrawn.
02
Drugs
estramustine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02853071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02853071.